文献速递乳腺乳腺X线

乳腺癌症筛查中数字乳腺断层合成与数字乳腺X线摄影的假阴性率比较

False-Negative Rates of Breast Cancer Screening with and without Digital Breast Tomosynthesis.
PubMed 文献 · Radiology · 2020-12-01

这项回顾性研究纳入10家学术与社区机构的380 641次筛查检查,比较数字乳腺断层合成(DBT)与数字乳腺X线摄影(DM)的假阴性率及筛查性能。DBT组总体假阴性率与症状性假阴性率均呈降低趋势但未达统计学显著,DBT组敏感度(89.8% vs 85.6%)和特异度(90.7% vs 89.1%)均优于DM组。DBT检出的癌症更多为浸润性,且淋巴结阳性与远处转移更少。

要点

  • DBT筛查敏感度89.8%、特异度90.7%,均高于DM的85.6%和89.1%。
  • 总体假阴性率DBT 0.6/1000次筛查 vs DM 0.7/1000次筛查,差异未达统计学显著(P=.20)。
  • DBT检出的癌症更常为浸润性,淋巴结阳性和远处转移更少。

核心结论

  • DBT筛查较DM提高敏感度与特异度,检出更多浸润性癌且淋巴结或远处转移更少;总体及症状性假阴性率呈降低趋势但未达统计学显著。

研究设计与样本

  • 回顾性研究,纳入10家学术与社区机构共380 641次筛查检查(DBT 183 989次,DM 196 652次),DM为DBT实施前1年检查,DBT为实施日起至2013年6月30日检查,随访癌症至2014年6月30日,数据收集于2016年、分析于2018-2019年,以癌症随访为参考标准。

关键影像表现/征象

  • DBT检出的癌症更常为浸润性(P<.001)。
  • DBT检出癌症的阳性淋巴结更少(P=.04),远处转移更少(P=.01)。
  • DBT检出晚期癌作为假阴性发现的比值比为0.9(95%CI:0.5,1.5)。

诊断标准与关键数值

  • 总体假阴性率:DBT 0.6/1000次筛查 vs DM 0.7/1000次筛查(P=.20)。
  • 症状性假阴性率:DBT 0.4/1000次筛查 vs DM 0.5/1000次筛查(P=.21)。
  • 致密乳腺女性无症状假阴性率:DBT 0.14/1000次筛查 vs DM 0.07/1000次筛查(P=.07)。
  • 敏感度:DBT 89.8%(966/1076例癌症)vs DM 85.6%(789/922例癌症)(P=.004)。
  • 特异度:DBT 90.7%(165 830/182 913次检查)vs DM 89.1%(174 480/195 730次检查)(P<.001)。

临床应用与阅片要点

  • DBT筛查可提高乳腺癌检出敏感度与特异度,阅片时可结合其三维断层优势评估致密乳腺。
  • DBT检出的癌症更多为浸润性且淋巴结或远处转移更少,提示其可能检出预后更有利的癌症。
  • 总体及症状性假阴性率在DBT组呈降低趋势但未达统计学显著,报告时不应表述为显著降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Screening with digital breast tomosynthesis (DBT) improves breast cancer detection and recall rates compared with those obtained with digital mammography (DM); however, the impact of DBT on patient survival has not been established. False-negative (FN) screening examinations can be a surrogate for long-term outcomes, such as breast cancer morbidity and mortality. Purpose To determine if screening with DBT is associated with lower FN rates, detection of cancers with more favorable prognoses, and improved performance outcomes versus DM. Materials and Methods This retrospective study involved 10 academic and community practices. DM screening examinations 1 year prior to DBT implementation and DBT screening examinations from the start date until June 30, 2013, were linked to cancers through June 30, 2014, with data collection in 2016 and analysis in 2018-2019. Cancers after FN examinations were characterized by presentation, either symptomatic or asymptomatic. FN rates, sensitivity, specificity, cancer detection and recall rates, positive predictive values, tumor size, histologic features, and receptor profile were compared. Results A total of 380 641 screening examinations were included. There were 183 989 DBT and 196 652 DM examinations. With DBT, rates trended lower for overall FN examinations (DBT, 0.6 per 1000 screens; DM, 0.7 per 1000 screens; P = .20) and symptomatic FN examinations (DBT, 0.4 per 1000 screens; DM, 0.5 per 1000 screens; P = .21). Asymptomatic FN rates trended higher in women with dense breasts (DBT, 0.14 per 1000 screens; DM: 0.07 per 1000 screens; P = .07). With DBT, improved sensitivity (DBT, 89.8% [966 of 1076 cancers]; DM, 85.6% [789 of 922 cancers]; P = .004) and specificity (DBT, 90.7% [165 830 of 182 913 examinations]; DM, 89.1% [174 480 of 195 730 examinations]; P < .001) were observed. Overall, cancers identified with DBT were more frequently invasive (P < .001), had fewer positive lymph nodes (P = .04) and distant metastases (P = .01), and had lower odds of an FN finding of advanced cancer (odds ratio, 0.9 [95% CI: 0.5, 1.5]). Conclusion Screening with digital breast tomosynthesis improves sensitivity and specificity and reveals more invasive cancers with fewer nodal or distant metastases. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Schattner in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Durand MA, Friedewald SM, Plecha DM, et al. False-Negative Rates of Breast Cancer Screening with and without Digital Breast Tomosynthesis. Radiology. 2020. PMID: 33258744. doi:10.1148/radiol.2020202858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。